Multi-stage biodegradable drug delivery platform

Patent metadata

Field	Value
Publication number	US-10130760-B2
Application number	US-201414218429-A
Country	US
Kind code	B2
Filing date	Mar 18, 2014
Priority date	Mar 15, 2013
Publication date	Nov 20, 2018
Grant date	Nov 20, 2018

Abstract

Embodiments of the invention provide multi-stage biodegradable drug delivery platforms and methods for the subcutaneous delivery of therapeutic agents (TA). Embodiments of the platform may be configured to subcutaneously deliver a first dose of a first TA which is absorbed into the body and/or blood stream (BBS) to produce a first therapeutic effect for a first selectable time period (STP), and subsequently after a second STP, deliver a second dose of a second TA which is absorbed into the BBS to produce a second therapeutic effect for a third STP. An embodiment of the platform may comprise a body having a tissue-penetrating end, a primary cavity having a first TA dose and a shell having a secondary cavity having a second TA dose. The first TA dose is released after the first STP and the second TA dose is released after the second STP by biodegradation of the shell.

First claim

The invention claimed is:

1. A method for multi-stage drug delivery, the method comprising:
lodging a drug delivery platform beneath the skin of a patient in a muscular tissue layer, the platform containing at least a first and second dosage of therapeutic agent, the first dosage contained in a first biodegradable structure, wherein the first biodegradable structure comprises a core body having a tissue penetrating end, the second dosage contained in a second biodegradable structure, the second structure being positioned inside the first structure, the second structure comprising a shell having a shell wall with a thickness of about 1 to about 20 thousandths of an inch and a weight of about 90 mg to about 150 mg, and configured to have a longer period of in vivo biodegradation for release of its therapeutic dosage than the first structure;
biodegrading the first structure in vivo over a first period of time until the integrity of the first structure is degraded sufficiently to release the first therapeutic agent dosage;
releasing the first therapeutic agent dosage into the tissue of the patient;
biodegrading the second structure in vivo over a second period of time until the integrity of the second structure is degraded sufficiently to release the second therapeutic agent dosage, wherein the entirety of the platform is biodegraded; and
releasing the second therapeutic agent dosage into the tissue of the patient after complete release of the first therapeutic agent dosage.

2. The method of claim 1 , wherein the core body is advanced through the patient's skin using a delivery structure which is detachably coupled to the core body, the delivery structure configured to be held in a user's fingers, the method further comprising:
lodging the core body into subcutaneous tissue using the delivery structure; and
detaching the core body from the delivery structure.

3. The method of claim 1 , wherein the core body is advanced through the patient's skin using a delivery apparatus.

4. The method of claim 1 , wherein the first and second therapeutic agent dosages comprise the same therapeutic agent.

5. The method of claim 4 , wherein the first and second therapeutic agent dosages comprise different amounts of the therapeutic agent.

6. The method of claim 1 , wherein the first and second therapeutic agent dosages comprise a vaccine.

7. The method of claim 1 , wherein the first and second therapeutic agent dosages comprise an antibiotic.

8. The method of claim 1 , wherein the second time period is substantially longer than the first time period.

9. The method of claim 8 , wherein the first time period is up to about 20 minutes.

10. The method of claim 8 , wherein the second time period is in a range from about one month to about three months.

11. The method of claim 8 , wherein the second time period is in a range from about three months to about six months.

12. The method of claim 8 , wherein the second time period is in a range from about six months to about twelve months.

13. The method of claim 8 , wherein first structure comprises a sugar or maltose.

14. The method of claim 8 , wherein the second structure comprises a magnesium alloy.

15. The method of claim 1 , wherein the shell wall comprises a first section of shell wall defining a first cavity which contains the second dose of therapeutic agent.

16. The method of claim 15 , wherein the second period of time is correlated to the thickness of the shell wall defining the first cavity.

17. The method of claim 15 , wherein the shell wall further comprises a second section of shell wall defining a second cavity containing a third dosage of therapeutic agent, the method further comprising:
biodegrading the second section of shell wall in vivo over a third period of time until the integrity of the second section of shell wall is degraded sufficiently to release the third therapeutic agent dosage; and
releasing the third therapeutic agent dosage into the tissue of the patient after complete release of the second therapeutic agent dosage.

18. The method of claim 17 , wherein the third period of time is correlated to the thickness of the shell wall defining the second cavity.

19. The method of claim 17 , wherein the third therapeutic agent dosage is released after the second therapeutic agent dosage.

20. The method of claim 17 , wherein the first, second and third therapeutic agent dosages comprise the same therapeutic agent.

21. The method of claim 1 , wherein the patient is a human.

22. The method of claim 1 , wherein the patient is a bovine.

23. A method for delivery of a multi dose vaccine regimen, wherein all of the doses of vaccine are inserted into a patient's body at the same time, the method comprising:
lodging a vaccine delivery platform beneath the skin of a patient in a muscular layer, the platform containing at least a first and second dosage of vaccine, the first dosage contained in a first biodegradable structure, wherein the first biodegradable structure comprises a core body having a tissue penetrating end, the second dosage contained in a second biodegradable structure, the second structure being positioned inside the first structure, the second structure comprises a shell having a shell wall with a thickness of about 1 to about 20 thousandths of an inch and a weight of about 90 mg to about 150 mg, the shell is comprised of a magnesium alloy comprising magnesium and at least one of zinc, manganese, aluminum, calcium, lithium, zirconium, or yttrium, and is configured to have a longer period of in vivo biodegradation for release of its vaccine dosage than the first structure;
biodegrading the first structure in vivo over a first period of time until the integrity of the first structure is degraded sufficiently to release the first vaccine dosage;
releasing the first vaccine dosage into the tissue of the patient;
biodegrading the second structure in vivo over a second period of time until the integrity of the second structure is degraded sufficiently to release the second vaccine dosage, wherein the entire platform is biodegraded; and
releasing the second vaccine dosage into the tissue of the patient after release of the first vaccine dosage.

24. The method of claim 23 , wherein the second period of time corresponds to a time period at which the patient's immunity to an antigen conferred by the first vaccine dosage has dropped below protective levels.

25. The method of claim 23 , wherein the second vaccine dosage is a booster dosage configured to increase the patient's immunity to the antigen conferred by the first vaccine dosage back to protective levels.

26. The method of claim 23 , wherein the vaccine regimen is a vaccine regimen for inoculation against a disease selected from the group consisting of Hepatitis A, Hepatitis B and Hepatitis C.

27. The method of claim 23 , wherein the vaccine regimen comprises a Td/Tdap vaccine regimen.

28. The method of claim 23 , wherein the vaccine regimen comprises a Tetanus vaccine regimen.

29. The method of claim 23 , wherein the vaccine regimen comprises an HPV vaccine regimen.

30. The method of claim 23 , wherein the vaccine regimen comprises a Varicella vaccine regimen.

31. The method of claim 23 , wherein the vaccine regimen comprises a meningococcal vaccine regimen.

32. The

Assignees

• Incube Labs Llc

Inventors

• Imran Mir

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/20

  for DNA viruses · CPC title

• A61P31/04

  Antibacterial agents · CPC title